Judge Advanced Claims Against ExThera Medical
A federal judge allowed negligence and wrongful death claims to move forward against the Bay Area firm.
Updated on Oct. 9, 2026 in Cancer
Families who sought care for metastatic cancer through the Bay Area company ExThera Medical Corporation saw their lawsuit gain momentum this week. A federal judge in San Francisco signaled she will allow negligence and wrongful death claims to move ahead.
Why it matters
The ruling marks a turn in a case involving allegations that the company falsely marketed its $45,000 ONCObind treatment as a cure for terminal illness. It brings the plaintiffs one step closer to addressing allegations that the treatment left patients sicker or led to their deaths.
ExThera marketed ONCObind at a cost of $45,000 per round, a figure that is now at the center of a federal fraud and liability suit. While the court has cleared the way for additional negligence claims, a formal ruling is still pending.
The players
ExThera Medical Corporation
A Bay Area-based medical company facing allegations of false marketing regarding its cancer treatment.
The details
The court reviewed a first amended complaint that included medical testimony alleging the company's actions contributed to patient deaths. The judge indicated that plaintiffs had successfully addressed previous legal defects in their negligence and wrongful death arguments. While fraud and liability claims were already active, this expansion allows the case to proceed on more comprehensive grounds.
Timeline
March 2025: Plaintiffs filed the initial lawsuit against the company.
May 2026: The judge dismissed several initial claims.
October 9, 2026: The judge indicated her intent to advance additional claims.
Across the Bay
This case follows a pattern set by the 2018 prosecution of the Burzynski Research Institute for deceptive cancer treatment practices. It signals a shift toward stricter judicial oversight regarding the marketing of high-cost, unproven medical therapies to patients seeking alternatives.
Residents following this local case should watch for the court's upcoming formal ruling on the amended complaint. There are no immediate changes to local medical services, but the proceedings offer insight into ongoing oversight of Bay Area medical firms.
The takeaway
The court's decision underscores the high legal bar for claims involving experimental medical treatments. Continue to track the federal docket for the final ruling on these negligence and wrongful death claims.
Further reading
For more reporting on local health disputes, explore our archive on Cancer.
Source note: This article includes information reported by Court House News Service.
